Ficolins and the lectin pathway of complement in patients with systemic lupus erythematosus
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Ficolins and the lectin pathway of complement in patients with systemic lupus erythematosus. / Hein, Estrid; Nielsen, Louise Aas; Nielsen, Christoffer T; Munthe-Fog, Lea; Skjødt, Mikkel-Ole; Jacobsen, Søren; Garred, Peter.
In: Molecular Immunology, Vol. 63, No. 2, 02.2015, p. 209-214.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Ficolins and the lectin pathway of complement in patients with systemic lupus erythematosus
AU - Hein, Estrid
AU - Nielsen, Louise Aas
AU - Nielsen, Christoffer T
AU - Munthe-Fog, Lea
AU - Skjødt, Mikkel-Ole
AU - Jacobsen, Søren
AU - Garred, Peter
N1 - Copyright © 2014 Elsevier Ltd. All rights reserved.
PY - 2015/2
Y1 - 2015/2
N2 - The complement system plays a pathophysiological role in systemic lupus erythematosus (SLE). This study aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway and SLE. EDTA plasma samples from 68 Danish SLE patients and 29 healthy donors were included in the study. Plasma concentrations of Ficolin-1, -2, and -3 were determined in specific sandwich ELISAs. Lectin pathway activity via Ficolin-3 was measured in ELISA on acetylated bovine serum albumin (acBSA) and measured as Ficolin-3 binding and deposition of C4, C3 and the terminal complement complex (TCC). SLE patients had increased levels of Ficolin-3, 21.6μg/ml as compared to 17.0μg/ml in healthy controls (P=0.0098). The Ficolin-1 plasma concentration was negatively correlated with SLE Disease Activity Index (SLEDAI) (Rho=-0.29, P=0.015) and positively correlated to the [Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index] (SDI) (Rho=0.27, P=0.026). The Ficolin-1 concentration was also associated with the occurrence of arterial (P=0.0053) but not venous thrombosis (P=0.42). Finally, deposition of C4, C3 and TCC in the Ficolin-3 pathway were all correlated to SLEDAI, respectively (P<0.0076). The Ficolin-1 association to SLEDAI and SDI as well as arterial thrombosis shown in this study suggests that Ficolin-1 may be a potential new biomarker for patients with SLE. Furthermore, Ficolin-3 mediated complement activation may be valuable in monitoring disease activity in SLE patients due to the high sensitivity for complement consumption in the assay independent of the Ficolin-3 concentration.
AB - The complement system plays a pathophysiological role in systemic lupus erythematosus (SLE). This study aims to investigate whether an association exists between the ficolins that are part of the lectin complement pathway and SLE. EDTA plasma samples from 68 Danish SLE patients and 29 healthy donors were included in the study. Plasma concentrations of Ficolin-1, -2, and -3 were determined in specific sandwich ELISAs. Lectin pathway activity via Ficolin-3 was measured in ELISA on acetylated bovine serum albumin (acBSA) and measured as Ficolin-3 binding and deposition of C4, C3 and the terminal complement complex (TCC). SLE patients had increased levels of Ficolin-3, 21.6μg/ml as compared to 17.0μg/ml in healthy controls (P=0.0098). The Ficolin-1 plasma concentration was negatively correlated with SLE Disease Activity Index (SLEDAI) (Rho=-0.29, P=0.015) and positively correlated to the [Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index] (SDI) (Rho=0.27, P=0.026). The Ficolin-1 concentration was also associated with the occurrence of arterial (P=0.0053) but not venous thrombosis (P=0.42). Finally, deposition of C4, C3 and TCC in the Ficolin-3 pathway were all correlated to SLEDAI, respectively (P<0.0076). The Ficolin-1 association to SLEDAI and SDI as well as arterial thrombosis shown in this study suggests that Ficolin-1 may be a potential new biomarker for patients with SLE. Furthermore, Ficolin-3 mediated complement activation may be valuable in monitoring disease activity in SLE patients due to the high sensitivity for complement consumption in the assay independent of the Ficolin-3 concentration.
KW - Adult
KW - Aged
KW - Case-Control Studies
KW - Complement Pathway, Mannose-Binding Lectin
KW - Demography
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Humans
KW - Lectins
KW - Lupus Erythematosus, Systemic
KW - Male
KW - Middle Aged
KW - Statistics, Nonparametric
KW - Young Adult
U2 - 10.1016/j.molimm.2014.07.003
DO - 10.1016/j.molimm.2014.07.003
M3 - Journal article
C2 - 25069872
VL - 63
SP - 209
EP - 214
JO - Molecular Immunology
JF - Molecular Immunology
SN - 0161-5890
IS - 2
ER -
ID: 137743957